847584-69-4

Upstream product

• 3470-50-6 6-Hydroxy-1-tetralone 
• 13633-25-5 1-Bromo-4-phenylbutane 
• 847586-08-7 1-{[1-methyl-6-(4-phenylbutoxy)-3,4-dihydronaphthalen-2-yl]methyl}azetidine-3-carboxylic acid 
• 1314760-20-7 C₂₂H₂₄O₂ 
• 872710-28-6 4-methyl-7-(4-phenylbutoxy)-1,2-dihydronaphthalene 
• 1314760-19-4 C₂₁H₂₆O₂ 
• 847585-55-1 6-(4-phenylbutoxy)-3,4-dihydronaphthalen-1(2H)-one 

Relevant academic research and scientific papers

Discovery of S1P agonists with a dihydronaphthalene scaffold

Structure-activity relationship of sphingosine-1-phosphate receptor agonists was examined. Cinnamyl derivative 1 was modified to improve S1P 1 agonistic activity as well as selectivity over S1P3 agonistic activity. Dihydronaphthalene derivative 10d was identified as a potent S1P1 receptor agonist with high selectivity against S1P3 and enhanced efficacy in lowering peripheral lymphocyte counts in mice.

COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF

A compound having an ability to bind to an S1P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like. wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.